The Effect of Low Intensity Extracorporeal Low Energy Shock Wave Therapy on Stress Urinary Incontinence and Overactivity Bladder

Overactive Bladder Clinical Trial

Official title:

The Effect of Low Intensity Extracorporeal Low Energy Shock Wave Therapy on Stress Urinary Incontinence and Overactivity Bladder

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04059133
• Other study ID #: KMUHIRB-F(II)-20180010
• Status: Recruiting
• Phase: N/A
• Start date: February 27, 2018
• Est. completion date: July 31, 2020

Study information

• Verified date: August 2019
• Source: Kaohsiung Medical University Chung-Ho Memorial Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The hypothesis of the present study is low intensity extracorporeal low energy shock wave therapy (LiESWT) can decrease inflammatory disorders, increase pelvic floor blood supply, enhanced bladder stem cell activation, Using LiESWT can decrease bladder overactivity, eliminate urinary incontinence and improve stress urinary incontinence (SUI) and overactive bladder (OAB) symptoms. Therefore improve quality of life and improve social activity.

Description:

Clinical application of low intensity extracorporeal low energy shock wave therapy (LiESWT) (2000 to 3000 impulses in 0.20-0.25 millijoule/mm2 (mJ/mm2)) initiated wound healing, promoted angiogenesis, reduced the level of oxidative stress, induced the releasing of VEGF, stimulated proliferation and differentiation of stem cells, and resulted in the effect of anti-inflammatory and tissue regeneration. Generally, LiESWT was used clinically to improve tissue regeneration at tendon-bone junctions, ischemic cardiovascular disorders, skin wound healing, chronic injuries of soft tissues and erectile dysfunction.

LiESWT has also been shown to increase vascular endothelial growth factor (VEGF) expression in ischemic tissues in vivo and to promote angiogenesis and functional recovery in models of chronic myocardial ischemia, myocardial infarction, and peripheral artery disease. Importantly, the advantages of LiESWT include therapies without medication or surgery, outpatient therapies, short treatment sessions, no anesthesia required, and non-invasive therapy.

The hypothesis of the present study is LiESWT can decrease inflammatory disorders, increase pelvic floor blood supply, enhanced bladder stem cell activation, Using LiESWT can decrease bladder overactivity, eliminate urinary incontinence and improve stress urinary incontinence (SUI) and overactive bladder (OAB) symptoms. Therefore improve quality of life and improve social activity.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 180
• Est. completion date: July 31, 2020
• Est. primary completion date: July 31, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Women patients within 20~75 years old;

2. OAB symptoms for = 3 months;

3. Frequency of micturition = 8 times daytime as well as 2 times nighttime, and = 2 episodes of urgency per week;

4. Patients have a = 3 month history of experiencing Stress Urinary Incontinence (SUI) per week (self reported);

5. Patients with OAB symptoms including urgency or/and urgency incontinence, urinary frequency and nocturia in the previous 3 months without medical treatments: antimuscarinic or ß3 agonist therapy;

6. Patients can understand, obey order and finish the questionnaires;

7. Patients would like to sign the informed consent;

8. Signature of informed consent form.

Exclusion Criteria:

1. Urinary tract infection (UTI) at screening and recurrent UTI defined as = 3 UTIs in the previous 12 months;

2. Patients who have other disease: diabetes mellitus, spinal cord injury, stoke history, brain disease and neurogenic disease which can cause OAB;

3. Chronic urologic inflammatory condition (Interstitial cystitis, urethral syndrome, painful bladder syndrome);

4. Bladder stone;

5. History of carcinoma of the urinary tract;

6. Lower urinary tract surgery in the last 6 months;

7. Patients who have operation, wound or infection around perineum;

8. Patients who have catheterization due to poor voiding function of urine;

9. Patients who have severe cardiovascular disease;

10. Patients who have severe coagulopathy or liver failure or renal failure;

11. Patients who have underlying urologic cancer;

12. Subjects with gross hematuria;

13. Significant bladder outflow obstruction;

14. Previous pelvic radiation therapy or previous, current malignant disease of the pelvic organs or having received intravesical injection or electrostimulation in the past 12 months;

15. Drug or nondrug treatments of OAB (in the previous 14 days), Concomitant medications that affect detrusor activity;

16. Subjects with history of kidneys stones;

17. Treatable condition that could cause urinary incontinence or urgency;

18. Neurological impairment or psychiatric disorder preventing appropriate understanding of consent and ability to comply with site personnel instructions;

19. History of drug or alcohol abuse within the last 12 months;

20. Within 1 month before entering the test and receive low-energy in vitro shock wave treatment process using antibiotics or phosphodiesterase inhibitors type 5 (PDE5i);

21. There are chronic pelvic pains caused by the merger of other diseases or injuries;

22. Urinary incontinence need to install the catheter;

23. Severe cardiopulmonary disease or diabetes is obviously poor control;

24. Obvious coagulation dysfunction or liver and kidney dysfunction.

Related Conditions & MeSH terms

• Enuresis
• Overactive Bladder
• Stress Urinary Incontinence
• Urinary Bladder, Overactive
• Urinary Incontinence
• Urinary Incontinence, Stress

Intervention

Device:
• DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-Sham arm
Sham treatment (shock wave probe w/o energy)
• DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-LiESWT arm
Low intensity extracorporeal low energy shock wave treatment (shock wave probe w/ energy)

Locations

Country	Name	City	State
Taiwan	Kaohsiung Medical University Hospital	Kaohsiung

Sponsors (1)

Lead Sponsor	Collaborator
Kaohsiung Medical University Chung-Ho Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pad Weight Difference	The pad test quantifies in grams urinary loss through the absorbent weighing as a measure of stress urinary incontinence.	Data will be analyzed at study completion at approximately 3 years.
Primary	Overactive bladder symptoms scores (OABSS)	Change in OABSS scores during LiESWT treatment and follow-up period.	Data will be analyzed at study completion at approximately 3 years.
Primary	International Consultation on Incontinence Questionnaire -- Short Form (ICIQ-SF)	Change in ICIQ-SF scores during LiESWT treatment and follow-up period.	Data will be analyzed at study completion at approximately 3 years.
Primary	Urogenital distress inventory (UDI-6)	Change in UDI-6 scores during LiESWT treatment and follow-up period.	Data will be analyzed at study completion at approximately 3 years.
Primary	Incontinence impact questionnaire -7 (IIQ-7)	Change in IIQ-7 scores during LiESWT treatment and follow-up period.	Data will be analyzed at study completion at approximately 3 years.
Secondary	maximum flow rate(Qmax=cc/s)	The maximum flow rate is the most important uroflowmetry index to diagnose bladder outlet obstruction or bladder contractility.	Data will be analyzed at study completion at approximately 3 years.
Secondary	Uroflow	Uroflow curve pattern: There are 5 uroflow curve patterns, bell-shaped, tower-shaped, interrupted-shaped, staccato-shaped and plateau shaped by uroflowmetry. The shape is determined by detrusor contractility and influenced by abdominal straining, coordination with the bladder outlet musculature and any distal anatomic obstruction.	Data will be analyzed at study completion at approximately 3 years.
Secondary	postvoid residual urine volume (PVR)	PVR (cc): ultrasonographic bladder scan machines calculates bladder volume. PVR measurements in neurologically intact children are highly variable. PVR must be obtained immediately after voiding(<5min).	Data will be analyzed at study completion at approximately 3 years.
Secondary	3-day micturition diary	The mean number of Intake (ml), output (ml), average urine volume (ml), functional bladder capacity (ml), urinary frequency (times/24hrs), urgency (times), and nocturia (times) per 24 hours were calculated from the data recorded by the participant during the 3-day micturition diary period.	Data will be analyzed at study completion at approximately 3 years.